{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:03:25Z","timestamp":1791659005473,"version":"4.3.4"},"reference-count":0,"publisher":"American Academy of Audiology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["j am acad audiol"],"published-print":{"date-parts":[[2006,1,1]]},"abstract":"<jats:p>Although double-blind experimental designs are considered the gold standard for documenting treatment effectiveness, many treatments for M\u00e9ni\u00e8re's disease have not been evaluated using this methodology. Particularly with a disease characterized by exacerbation and remission,\n carefully controlled, long-term studies are required. The nature of the placebo effect is described in this article, and the concept of debonafide effect introduced. Ideally, patients should be given treatments supported by evidence-based medicine that have the lowest possible risk of side\n effects. However, risk minimization may dictate using treatments that have not been proven effective and may evoke debonafide effects. A pesar de que los dise\u00f1os experimentales a doble ciego se consideran el est\u00e1ndar de oro para documentar la efectividad de un tratamiento, muchas\n terapias para la enfermedad de M\u00e9ni\u00e8re no han sido evaluadas utilizando esta metodolog\u00eda. Con una enfermedad caracterizada particularmente por exacerbaciones y remisiones se requieren estudios cuidadosamente controlados y a largo plazo. Se describe en este art\u00edculo\n la naturaleza del efecto placebo y se introduce el concepto del efecto debonafide. Idealmente, los pacientes deber\u00edan recibir tratamientos apoyados por una medicina basada en evidencia que tengan el m\u00e1s bajo riesgo posible de efectos secundarios. Sin embargo, la minimizaci\u00f3n\n del riesgo puede dictar la utilizaci\u00f3n de tratamientos que no han demostrado ser efectivos y que pueden provocar efectos debonafide.<\/jats:p>","DOI":"10.3766\/jaaa.17.1.4","type":"journal-article","created":{"date-parts":[[2008,4,22]],"date-time":"2008-04-22T23:54:28Z","timestamp":1208908468000},"page":"27-37","source":"Crossref","is-referenced-by-count":8,"title":["Evaluating Treatments for M\u00e9ni\u00e8re's Disease: Controversies Surrounding Placebo Control"],"prefix":"10.3766","volume":"17","author":[{"given":"Teri A.","family":"Hamill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2087","container-title":["Journal of the American Academy of Audiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/aaa\/jaaa\/2006\/00000017\/00000001\/art00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T23:15:08Z","timestamp":1738797308000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.3766\/jaaa.17.1.4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,1]]},"references-count":0,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1,1]]}},"alternative-id":["1050-0545(20060101)17:1L.27;1-"],"URL":"https:\/\/doi.org\/10.3766\/jaaa.17.1.4","relation":{},"ISSN":["1050-0545"],"issn-type":[{"value":"1050-0545","type":"print"}],"subject":[],"published":{"date-parts":[[2006,1,1]]}}}